BLOG ABOUT BIOTECHNOLOGY TOPICS

Chimeras: multi-epitope bio-markers

Figure 1.Chimeras bio-markers

At Rekom Biotech we have specialized in the design and production of next-generation bio-markers: chimeras or multi-epitope bio-markers, which have improved their antigenic properties such as sensitivity and specificity.

Rekom Biotech chimeras bio-markers

Written by Ana Camacho.

Rekom Biotech in the 71th AACC Clinical Lab Expo

8/12/2019

Rekom Biotech has attended the 71th AACC Clinical Lab Expo in Anaheim, California. Our colleagues, Dr. Ana Camacho (CEO & CSO - Ph.D.) and Rosa Mª de Molina (Marketing Manager), presented our new products in both lines, recombinant antigens and allergens, and made very interesting collaborations. The event has been another successful meeting and we thank all the companies we met with at the trade show. We look forward to the next AACC Clinical Lab Expo.

Biotinylated bio-markers

Figure 1.Biotinylated Bio-marker

In many ways, a conjugated bio-marker can be the solution to different problems arisen in a new IVD test development. A common problem caused by most of the surfaces is protein denaturation due to the relatively high surface by hydrophobicity. Additionally, there may be larger steric influence on binding events due to the close proximity of the surface and the sensor molecules. The specific orientation may also improve the stability of attached proteins and increase the sensitivity of the assay by exposure of its antigenic regions.

Conventional conjugation methods generally work well with antibodies; however, results with many antigens of less well-established structures are less constant. This is probably the main reason why double-antigen sandwich ELISAs (DAS-ELISA) are not as commonly used for antibody detection as indirect ELISA.

To circumvent the effect on antigenic structure caused by conventional chemical conjugation that could result in decrease in sensitivity of DAS-ELISAs, Rekom Biotech has developed a product line of biotinylated antigens, offering to our customers the possibility to buy their favourite antigen but conjugated in its C-terminus. This molecule allows the specific interaction of the biotinylated antigens to the streptavidin protein.

Why biotinylated?

The extremely specific and high affinity binding of biotin by avidin and/or streptavidin (K_d ≈ 10^-14M) results in specific detection systems of very high sensitivity. A clear advantage of this system is that with a common strep-HRP, we can obtain conjugated complex of all our references without the necessity of performing the peroxidation of each reference.

The biotin is fused to a linker which maintains the molecule away to the antigen surface, avoiding steric hindrance between the biotin and the antigenic regions involved in Ab-binding. Thus, the Ab interaction will not be compromised with the conjugation.

Figure 2. Interaction between an antigen (green) vs Fab region of an Ab (pink). In red are specified the amino acids that usually are used in conjugation procedures. Some of these amino acids are part of the epitope region of the antigen. The conjugation would interfere with the Ab-binding, decreasing the antigenic capacity of the bio-marker.

As there is just one biotin per protein molecule, our conjugated bio-markers will show a higher inter-lot reproducibility and this will facilitate the reproducibility of our customers´ IVD test also.

Biotinylated applications

1. Antigen orientation in streptavidin-coated plates.
   
   
   
   
2. Detection in IgM capture assays.
   
   
   
   
3. Detection in DAS assays.
   
   
   
   
4. Bonding to gold and other nanoparticles coated with streptavidin.
   
   
   
   

Rekom Biotech biotinylated bio-markers

Written by Ana Camacho.

Rekom Biotech in MEDICA 2018

11/12/2018

Rekom Biotech has attended to MEDICA 2018. The fair was held in Düsseldorf from November 12th to 15th, 2018. The fair allowed us to consolidate the relationship with our customers as well as to explore new strategic alliances. In addition, we have been able to observe the new trends of the IVD market.